Sinclair Research Appoints Mark Lane as Director of Business Development
May. 16, 2018
COLUMBIA, Mo.--(BUSINESS WIRE)--May 16, 2018--Sinclair Research, one of the nation’s leading providers of preclinical services, is pleased to announce new executive leadership with the arrival of Mark Lane, as director of business development. In this role, Lane will have responsibility for the San Francisco to Seattle corridor. He will be responsible for driving the growth of Sinclair’s IND enabling toxicology and efficacy models and fostering positive relationships with new and current customers.
Lane joins Sinclair with more than 25 years of experience in the contract research organization (CRO) industry. He has extensive experience in DMPK, safety pharmacology, experimental therapeutics and molecular imaging. He is published in various journals and is an active member of professional organizations, including the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Society for Whole-Body Autoradiography (SWBA), American Association for Cancer Research (AACR) and American College of Toxicology (ACT). His preclinical market knowledge and experience from the pharmaceutical and CRO industries will be of significant value to Sinclair and all its customers.
“Sinclair is fortunate to recruit such an outstanding industry veteran. Mark’s industry knowledge and welcoming style are a great fit for our company and our market,” said Mark Crane, vice president of business development.
About Sinclair Research Sinclair Research Center, a preclinical contract research organization (CRO) established in 1964, offers animal efficacy models, IND enabling toxicology services and research capabilities to animal health and medical device companies. Our clients include large, mid-tier, small and startup companies in both human and animal health markets. With more than 50 years’ experience, Sinclair is the undisputed expert in all breeds of miniature swine. In addition, we manage many standing animal colony models including diabetes, wound healing, irritable bowel disease and general PK, and we have developed and maintain our own unique research breed of mini-swine, “The Sinclair Pig.”
View source version on businesswire.com:https://www.businesswire.com/news/home/20180516005092/en/
CONTACT: For Sinclair Research
Lea Studer, 402-366-1752
KEYWORD: UNITED STATES NORTH AMERICA MISSOURI
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL RESEARCH SCIENCE
SOURCE: Sinclair Research
Copyright Business Wire 2018.
PUB: 05/16/2018 08:00 AM/DISC: 05/16/2018 08:01 AM